IPP Bureau
Finerenone hits major goal in Phase III FIND-CKD trial
By IPP Bureau - March 16, 2026
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals marks 75-year journey of global healthcare innovation
By IPP Bureau - March 16, 2026
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Dr. Jitendra Singh lays Foundation for Rs 600 crore Orchid Bio-Pharma plant in Kathua
By IPP Bureau - March 16, 2026
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes
By IPP Bureau - March 16, 2026
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
China’s NMPA approves Zydus-licensed anaemia drug Desidustat
By IPP Bureau - March 15, 2026
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies
By IPP Bureau - March 14, 2026
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
By IPP Bureau - March 14, 2026
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
By IPP Bureau - March 14, 2026
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
By IPP Bureau - March 14, 2026
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Almirall opens Shanghai hub to power dermatology innovation and China partnerships
By IPP Bureau - March 14, 2026
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
By IPP Bureau - March 14, 2026
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
GelMEDIX partners with Catalent to advance vision-restoring cell therapies
By IPP Bureau - March 14, 2026
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Veristat expands global trial & regulatory services as Chinese drugmakers push overseas
By IPP Bureau - March 14, 2026
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Biogen unveils promising new data for Salanersen in kids with SMA
By IPP Bureau - March 14, 2026
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Zydus receives USFDA approval for cevimeline hydrochloride capsules
By IPP Bureau - March 14, 2026
Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.
